Arthneeti

Arvee Laboratories (India) Share Price & Earnings Call Analysis

₹213.80+1.74% today
Market cap
₹236 Cr
P/E
58.17
ROE
7.32%
PEG
-3.50
Price to sales
5.71
Debt to equity
0.03
52W high / low
₹291 / ₹134
Sales growth (5Y)
-7.83%
EBITDA margin
12.94%
Net profit margin
7.55%
Promoter holding
73.50%
Sales (last year)
₹41 Cr

Incorporated in 2012, Arvee Laboratories India Ltd manufactures specialized chemicals[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Arvee Laboratories (India) rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Chemicals & Petrochemicals companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 0–2%₹234 Cr3.0
240%+Flat₹3,888 Cr48.5
340%+Flat₹3,514 Cr4.3
440%+Flat₹180 Cr11.9
540%+Flat₹138 Cr15.1
620–40%Up 2%+₹1.70L Cr85.4

Sign up free to see every company in the sector ranking and track Arvee Laboratories (India).

Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals ranking

Financials of Arvee Laboratories (India)

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Arvee Laboratories (India)

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +73.50%73.50%73.50%73.50%73.50%73.50%73.50%73.50%73.50%73.50%73.50%73.50%
Public +26.50%26.50%26.50%26.50%26.50%26.50%26.50%26.50%26.50%26.50%26.50%26.50%
No. of Shareholders1,3721,2981,4801,4161,6231,5761,5051,5051,8611,6381,5961,947

Financials of Arvee Laboratories (India)

Quarterly Results

Quarter-by-quarter operating performance

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +7.608.917.706.1410.6012.538.916.457.483.459.7810.8017.23
YoY Sales growth-58.20%-60.82%-52.62%-51.11%+39.47%+40.63%+15.71%+5.05%-29.43%-72.47%+9.76%+67.44%+130.35%
Expenses +6.628.227.175.359.0611.038.576.237.143.338.159.7014.74
Operating Profit0.980.690.530.791.541.500.340.220.340.121.631.102.49
OPM %12.89%7.74%6.88%12.87%14.53%11.97%3.82%3.41%4.55%3.48%16.67%10.19%14.45%
Other Income +0.090.090.190.210.110.160.190.210.170.230.140.150.18
Interest0.070.080.050.050.080.050.050.070.040.040.070.080.06
Depreciation0.350.420.350.370.310.300.280.270.290.300.300.310.32
Profit before tax0.650.280.320.581.261.310.200.090.180.011.400.862.29
Tax %24.62%25.00%25.00%81.03%25.40%25.19%25.00%22.22%5.56%0.00%-30.71%38.37%26.20%
Net Profit +0.490.210.240.120.940.980.150.070.170.011.830.521.69
EPS in Rs0.440.190.220.110.850.890.140.060.150.011.660.471.53

Financials of Arvee Laboratories (India)

Profit & Loss

Annual income statement trend

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +26.8234.4447.7854.9045.4247.3840.3361.3530.3538.4931.5141.26
Sales growth+28.41%+38.73%+14.90%-17.27%+4.32%-14.88%+52.12%-50.53%+26.82%-18.13%+16.65%
Expenses +21.8328.5440.6148.7339.4041.3134.6554.0627.4134.8828.3335.92
Operating Profit4.995.907.176.176.026.075.687.292.943.613.185.34
OPM %18.61%17.13%15.01%11.24%13.25%12.81%14.08%11.88%9.69%9.38%10.09%12.94%
Other Income +0.100.510.230.350.350.560.461.350.640.660.690.70
Interest3.073.483.331.630.990.580.370.390.250.250.230.25
Depreciation1.492.072.152.352.292.412.322.081.501.151.211.23
Profit before tax0.530.861.922.543.093.643.456.171.832.872.434.56
Tax %66.04%-81.40%43.23%11.02%25.89%26.37%25.51%33.23%42.62%25.09%-3.70%
Net Profit +0.191.551.092.262.302.682.574.121.052.152.534.05
EPS in Rs0.231.910.992.052.092.432.333.740.951.952.303.67
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Arvee Laboratories (India)

Balance Sheet

Capital structure and asset base

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital4.054.055.515.515.5111.0211.0211.0211.0211.0211.02
Reserves-1.410.158.6910.9513.2510.4212.9217.0418.0920.2422.77
Borrowings +25.3224.9916.1512.873.878.883.131.001.001.031.11
Other Liabilities +7.256.4913.777.8111.0010.7311.619.638.455.297.99
Total Liabilities35.2135.6844.1237.1433.6341.0538.6838.6938.5637.5842.89
Fixed Assets +13.1516.8814.8812.6513.1813.8113.8412.6812.6715.2716.72
CWIP4.300.001.182.321.780.970.981.532.620.730.90
Investments0.000.000.001.953.092.030.000.000.000.001.70
Other Assets +17.7618.8028.0620.2215.5824.2423.8624.4823.2721.5823.57
Total Assets35.2135.6844.1237.1433.6341.0538.6838.6938.5637.5842.89

Financials of Arvee Laboratories (India)

Cash Flows

Operating, investing and financing cash movement

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +4.036.029.4610.311.710.682.933.66-0.21-0.12
Cash from Investing Activity +-1.40-1.23-2.85-3.08-0.600.06-1.26-2.16-1.320.50
Cash from Financing Activity +-2.92-3.78-4.92-9.904.52-6.06-2.42-0.19-0.12-0.16
Net Cash Flow-0.291.001.68-2.675.63-5.32-0.751.31-1.640.23
Free Cash Flow2.544.687.968.02-0.53-1.681.471.07-2.06-2.95
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit57%96%158%184%44%29%64%139%10%3%

Financials of Arvee Laboratories (India)

Ratios

Working capital efficiency and return ratios

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days82.6187.12118.2552.6652.4060.70109.7872.9473.4879.66121.05
Inventory Days155.08104.5399.6142.9080.9691.9693.2442.29159.0280.31228.81
Days Payable130.7398.14150.0355.84125.63118.08160.1273.30164.4957.72159.35
Cash Conversion Cycle106.9693.5067.8439.727.7234.5942.9041.9468.01102.25190.51
Working Capital Days30.0830.8430.79-6.5210.29-10.6349.9670.4495.97103.55168.43
ROCE %15.19%17.64%13.67%14.90%14.92%12.89%23.34%6.83%9.58%7.53%

Continue your research

Others in Chemicals & Petrochemicals this season

  • J.G.Chemicals (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹3,610 million, up 63.9% YoY (₹2,203 million in Q2 FY26) (Page 23) . Key investor presentation takeaways from J.G.Chemicals Ltd

  • Lords Chloro (Q2 FY27)

    115.40 Crore, up 17.34% YoY from Rs. Key investor presentation takeaways from Lords Chloro Alkali Ltd's Q2 FY27 investor presentation — and how it ranks against

  • Camlin Fine (Q2 FY27)

    Q2 FY27 revenue: Rs 4,915 mn, up 9.15% YoY from Rs 4,503 mn in Q2 FY26 (Page 6, 9) . Key investor presentation takeaways from Camlin Fine Sciences Ltd's Q2 FY27

  • Gujarat Fluoroch (Q2 FY27)

    Consolidated Q2FY27 revenue: ₹1,760 crore, up 45% YoY (Q2FY26: ₹1,210 crore). Key investor presentation takeaways from Gujarat Fluorochemicals Ltd's Q2 FY27 inv

Compare:vs Solar Industriesvs Pidilite Industriesvs SRF